ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "ZIOPHARM Oncology, Inc." (ZIOP) Report Updated: Dec 07, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"ZIOPHARM Oncology, Inc." (ZIOP)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: EXEL,ARIA,VNDA,MNOV

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: D down no change
Last Week: D same upgrade
Two Weeks Ago: F up downgrade
service keys

"ZIOPHARM Oncology, Inc."© quotemedia

Company Profile

ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in collaboration with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability. The company is also developing programs in various stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System(r) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. Its pipeline includes various gene and cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The company has collaboration with Intrexon Corporation. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.